Polyclonal Antibody Market

Global Polyclonal Antibody Market Size, Share & Trends Analysis Report, By Type (Primary Antibody and Secondary Antibody), By Application (Academic Research and Commercial), Forecast (2022-2028)
    Update Available - Forecast 2024-2030   

Published: Jul 2023 | Report Code: OMR2026108 | Category : Healthcare Information Technology | Delivery Format: /

The global polyclonal antibody market is anticipated to grow at a significant CAGR 5.1% during the forecast period (2022-2028). These antibodies are defined as a composition of a mixture of antibodies that correspond to the natural immune response to an antigen and are highly used in general research applications. The major factor attributable to the market growth includes the increasing application of polyclonal antibody in various research applications. Adding to this, the rising incidence of cancer backed by the significant rise in awareness campaigns and research funding on cancer, is likely to boost further use of polyclonal antibodies in the disease treatment. For instance, in 2018, the UK Government funded around $300 million for cancer treatment. Further, key initiatives by the market players also provide a major boost to the market growth. For instance, in March 2020, GigaGen, Inc., a biotechnology company, announced that it has developed a recombinant polyclonal antibody therapy for the treatment of COVID-19.

Some key players operating in the market include Thermo Fisher Scientific Inc., Agilent Technologies, Inc., and PerkinElmer, Inc., among others. The market players are eyeing on strengthening their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, investment in research and development, and so on. For instance, in August 2018, SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, announced that its anti-Ebola immunotherapy, SAB-139, offers100% protection against a lethal dose of the Ebola virus in an animal study published in The Journal of Infectious Diseases. The study was conducted by the National Interagency Confederation for Biological Research in collaboration with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Naval Medical Research Center (NMRC).

Market Coverage

The market number available for – 2021-2028

Base year- 2021

Forecast period- 2022-2028

Segment Covered- 

o By Type

o By Application 

Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape: Thermo Fisher Scientific Inc., Agilent Technologies, Inc., and PerkinElmer, Inc., among others.

Key questions addressed by the report

What is the market growth rate?

Which segment and region dominate the market in the base year?

Which segment and region will project the fastest growth in the market?

How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

Who is the leader in the market?

How are players addressing challenges to sustain growth?

Where is the investment opportunity?

Global Polyclonal Antibody Market Report by Segment

By Type

Primary Antibody

Secondary Antibody

By Application

Academic Research

Commercial

Global Polyclonal Antibody Market Report by Region

North America       

US

Canada

Europe

Germany

UK

France

Spain

Italy

Rest of Europe

Asia-Pacific    

China

Japan

India

Rest of Asia-Pacific

Rest of the World

Latin America

Middle East and Africa